Valuation: TTY Biopharm Company Limited

Market Cap 19.47B 613M 538M 508M 463M 866M 58.72B 872M 6.08B 2.35B 30B 2.3B 2.25B 96.41B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 19.47B 613M 538M 508M 463M 866M 58.72B 872M 6.08B 2.35B 30B 2.3B 2.25B 96.41B EV / Sales 2026 *
2.76x
EV / Sales 2027 * -
Free-Float
76.55%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week-0.13%
Current month+0.64%
1 month+0.64%
3 months+4.82%
6 months-2.12%
Current year-3.93%
1 week 78.1
Extreme 78.1
79.3
1 month 76.3
Extreme 76.3
79.3
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
137
Manager TitleAgeSince
Chief Executive Officer - 2022-04-17
Director of Finance/CFO - 2015-12-30
Compliance Officer - 2022-04-17
Director TitleAgeSince
Director/Board Member - 1995-07-23
Director/Board Member - 2016-06-23
Director/Board Member 70 2016-06-23
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-0.13%+1.03%+2.49% 613M
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.27%+0.65%+27.73%+43.97% 363.9B
Weighted average by Cap. +0.02%+1.32%+41.53%+67.82%

Financials

2026 *2027 *
Net sales 7.05B 222M 195M 184M 167M 313M 21.25B 316M 2.2B 852M 10.86B 832M 814M 34.89B -
Net income - -
Net Debt - -
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-09-24 NT$78.30 -0.51% 203,251
26-09-23 NT$78.70 -0.38% 227,443
26-09-22 NT$79.00 -0.13% 406,838
26-09-21 NT$79.10 +0.89% 603,283
26-09-18 NT$78.40 -0.25% 441,768
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
78.30TWD
Average target price
92.00TWD
Spread / Average Target
+17.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4105 Stock